Princeton to give out meningitis vaccine not approved in the U.S.
Share Now on:
Princeton University will offer its on-campus students and some staff special meningitis vaccine that has been approved in Europe and Australia, but not in the United States. The move comes after the Food and Drug Administration gave its approval to importing the Bexsero vaccine for use on the campus. The university wants to stop the spread of type B meningococcal bacteria, which is rare in the US and potentially deadly. Since March, there have been seven cases of the infection at Princeton’s campus in New Jersey.
Getting such emergency approval for a medicine is also rare but it has precedent, says Daniel Carpenter, a professor of Government at Harvard and expert on FDA regulation.
“Princeton and the Center for Disease Control in Atlanta both made the request to the FDA,” Carpenter says. “The concern is that because these students are on campus, there’s kind of a localized risk of infection, and hence the need for the vaccine would also more local. And, so, I think the FDA sees this as a containable situation where they don’t have to approve a large-scale exception to the rules.”
We’re here to help you navigate this changed world and economy.
Our mission at Marketplace is to raise the economic intelligence of the country. It’s a tough task, but it’s never been more important.
In the past year, we’ve seen record unemployment, stimulus bills, and reddit users influencing the stock market. Marketplace helps you understand it all, will fact-based, approachable, and unbiased reporting.
Generous support from listeners and readers is what powers our nonprofit news—and your donation today will help provide this essential service. For just $5/month, you can sustain independent journalism that keeps you and thousands of others informed.